FDA, CMS Coordination On Coverage Decisions May Improve Under McClellan
This article was originally published in The Gray Sheet
Executive Summary
FDA and the Centers for Medicare & Medicaid Services are likely to have a closer relationship under the tenure of incoming commissioner Mark McClellan, MD/PhD
You may also be interested in...
FDA Review Criteria Are Insufficient To Prompt CMS Coverage – Feigal, Tunis
Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11
FDA Review Criteria Are Insufficient To Prompt CMS Coverage – Feigal, Tunis
Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11
McClellan FDA Commissioner Nomination Likely On Senate Fast Track
The Senate Health, Education, Labor & Pensions Committee appears to be fast-tracking the confirmation process for FDA Commissioner-nominee Mark McClellan, MD/PhD